Frankfurt. Global law firm K&L Gates LLP has advised Luye Pharma Group Ltd.‎ in connection with its market entry into Europe. Through a bidding process initiated by Avista Capital Partners and Nordic Capital, Luye succeeded in acquiring Acino’s transdermal drug delivery systems consisting of patches and biodegradable subcutaneous implants. The parties agreed that a carve-out of other business sectors of Acino shall be consummated prior to the closing of the transaction.

Listed on the Hong Kong Stock Exchange, Luye Pharma Group Ltd.‎ develops and manufactures medicinal products. K&L Gates was chosen for the matter because of the seamless cooperation of its Chinese and German practice groups as well as its specific knowledge in the pharmaceutical industry sector.

The K&L Gates team that advised Luye on the deal included partners Claudius Paul (Lead, Corporate/M&A), Volker Gattringer (China Group, Corporate/M&A), and Dr. Mathias Schulze Steinen (Corporate/M&A), all Frankfurt; Frank Voon (Corporate/M&A, Beijing); Dr. Thorsten Vormann (IP Litigation, Frankfurt); Dr. Friederike Gräfin von Brühl (TMT, Berlin); Nicolas Roggel (Employment Law, Berlin); Rainer Schmitt (Tax, Frankfurt); and Dr. Annette Mutschler-Siebert (Competition Law, Berlin), as well as associates Tom Pagels and Dr. Arthur von Gruenewaldt (both Corporate/M&A, Frankfurt); Andreas Menge (Corporate/M&A, Berlin); Dr. Thomas Nietsch (TMT, Berlin); Dr. Isabel Kainer-Pfuhl and Marc-Ruben Hagedorn (both IP Litigation, Frankfurt); Nils Neumann (Employment Law, Berlin); and Marion Baumann (Competition Law, Berlin); and Yiqing Huang (China Group, Corporate/M&A), a PRC-qualified lawyer in Frankfurt.